Publications
Alvarez-Perez B.; Poras H.; Maldonado R.. The inhibition of enkephalin catabolism by dual enkephalinase inhibitor: A novel possible therapeutic approach for opioid use disorders. British Journal of Pharmacology 2023; ( ). |
Cajiao-Manrique MDM, Maldonado R, Martín-García E. A male mouse model of WIN 55,212-2 self-administration to study cannabinoid addiction. Frontiers in Pharmacology 2023; 14( ). |
Cai H, Chen X, Burokas A, Maldonado R. Editorial: gut microbiota as a therapeutic target in neuropsychiatric disorders: current status and future directions. Frontiers in Neuroscience 2023; 17( ). |
Martinez-Torres S.; Bergada-Martinez A.; Ortega J.E.; Galera-Lopez L.; Hervera A.; de los Reyes-Ramirez L.; Ortega-Alvaro A.; Remmers F.; Muñoz-Moreno E.; Soria G.; del Rio J.A.; Lutz B.; Ruiz-Ortega J.A.; Meana J.J.; Maldonado R.; Ozaita A.. Peripheral CB1 receptor blockade acts as a memory enhancer through a noradrenergic mechanism [In press]. Neuropsychopharmacology 2023; ( ). |
Garcia-Blanco A, Ramirez-Lopez, Navarrete F, Garcia-Gutierrez MS, Manzanares J, Martin-Garcia E, Maldonado R. Role of CB2 cannabinoid receptor in the development of food addiction in male mice. Neurobiology of Disease 2023; 179(0). |
Barrera-Conde M.; Veza-Estevez E.; Gomis-Gonzalez M.; Garcia-Quintana J.; Trabsa A.; Martinez-Sadurni L.; Pujades M.; Perez V.; de la Torre R.; Berge D.; Robledo P.. Role of cyclin-dependent kinase 5 in psychosis and the modulatory effects of cannabinoids. Neurobiology of Disease 2023; 176( ). |
Haney M, Vallée M, Fabre S, Collins Reed S, Zanese M, Campistron G, et al. Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: phase 1 and phase 2a randomized trials. Nature Medicine 2023; 29(6): 1487-99. |
Cajiao-Manrique MM, Casadó-Anguera V, García-Blanco A, Maldonado R, Martín-García E. THC exposure during adolescence increases impulsivity-like behavior in adulthood in a WIN 55,212-2 self-administration mouse model. Frontiers in Psychiatry 2023; 14( ). |
Picon-Pages P.; Fanlo-Ucar H.; Herrera-Fernandez V.; Auselle-Bosch S.; Galera-Lopez L.; Gutierrez D.A.; Ozaita A.; Alvarez A.R.; Oliva B.; Muñoz F.J.. Amyloid ß-peptide causes the permanent activation of CaMKII¿ through its oxidation. International Journal of Molecular Sciences 2022; 23(23). |
Navarro-Romero A.; Galera-Lopez L.; Ortiz-Romero P.; Llorente-Ovejero A.; de los Reyes-Ramirez L.; de Tena I.B.; Garcia-Elias A.; Mas-Stachurska A.; Reixachs-Sole M.; Pastor A.; de la Torre R.; Maldonado R.; Benito B.; Eyras E.; Rodriguez-Puertas R.; Campuzano V.; Ozaita A.. Cannabinoid signaling modulation through JZL184 restores key phenotypes of a mouse model for Williams-Beuren syndrome. eLife 2022; 11( ). |